Abstracts tagged "Biologic agents"

Abstract Number: 2456 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
Claudia A. Salinas¹, Lucy Mitchell², Jon T. Giles³, Thomas Dörner⁴ and Stephen P. Motsko¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapols, IN, ³Columbia University, College of Physicians and Surgeons, New York, NY, ⁴Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany
Background/Purpose: Patients with RA have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT) compared to non-RA populations1. …
Abstract Number: 1226 • 2018 ACR/ARHP Annual Meeting
Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis
Sho Fukui¹, Masei Suda², Haruki Sawada³, Yukihiko Ikeda¹, Mitsuru Watanabe⁴, Ayako Koido⁴, Rui Kawato⁵, Yasuhiro Suyama⁶, Hisanori Shimizu⁷, Haruyuki Yanaoka⁷, Ryo Rokutanda¹, Hiromichi Tamaki¹, Tokutaro Tsuda¹, Ken-ichi Yamaguchi⁸, Mitsumasa Kishimoto¹ and Masato Okada⁹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno-Rheumatology Center, St luke's International hospital, Tokyo, Japan, ³Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Immune-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁵Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan, ⁶Division of Rheumatology, JR Tokyo General Hospital, Tokyo, Japan, ⁷St. Luke's International Hospital, Tokyo, Japan, ⁸Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Biologics are widely used and effective treatments for rheumatoid arthritis (RA), but generally biologics are avoided when patients have active infections on the day…
Abstract Number: 2461 • 2018 ACR/ARHP Annual Meeting
Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Pia Mercedes Lois¹, Cristina Vadillo Font¹, Dalifer Freites Núñez², Isabel Hernández-Rodríguez¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…
Abstract Number: 1227 • 2018 ACR/ARHP Annual Meeting
Indicator Opportunistic Infections after Biological Treatment in Rheumatoid Arthritis, 10 Years Follow up in Clinical Practice
Leticia Leon^1,2, Marina Peñuelas³, Francisco Javier Candel³, Dalifer Freites Núñez⁴, Luis Rodriguez-Rodriguez⁵, Zulema Rosales Rosado⁶ and Lydia A Alcazar⁷, ¹Rheumatology Department, Hospital Clínical San Carlos, and IdISSC, Madrid, Spain, ²Health Sciences, Universidad Camilo Jose Cela, Madrid, Spain, ³Microbiology, Microbiology Department. Hospital Clínico San Carlos, Madrid, Spain., Madrid, Spain, ⁴Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁶Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ⁷Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) may be associated with opportunistic infections. Our purposes were to describe their incidence in Rheumatoid Arthritis (RA) taking bDMARDs,…
Abstract Number: 2489 • 2018 ACR/ARHP Annual Meeting
In Clinical Practice a Substantial Group of Rheumatoid Arthritis (RA) Patients on Biologic Therapy (bDMARDs) Has Persistent Moderate Disease Activity Despite Treatment Switches That Correlates with Unfavourable Long-Term Outcome
Irini Genitsaridi^1,2, Irini Flouri³, Argyro Repa², Nestor Avgoustidis², Nikolaos Kougkas², Ioannis Papalopoulos², Styliani Polia², Konstantinos Marias¹, Dimitris Plexousakis⁴, George Bertsias² and Prodromos Sidiropoulos², ¹Computational BioMedicine Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece, ²Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklion, Greece, ³Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, School of Medicine, Heraklio, Greece, ⁴Information Systems Laboratory, Institute of Computer Science, Foundation for Research and Technology-Hellas, Heraklio, Greece
Background/Purpose: Registry data have shown that treatment with bDMARDs induces remission or LDA (RLDA) in up-to 50% of RA patients. Approximately 30-50% of patients have…
Abstract Number: 1251 • 2018 ACR/ARHP Annual Meeting
Guideline Adherence for Perioperative Use of Immunosuppressive Medications in Patients with Rheumatologic Disease
Grace Berlin, Carolyn Casey, Susan Kim and James Ross, Rheumatology, Lehigh Valley Health Network, Allentown, PA
Background/Purpose: In response to the lack of clear data to dictate recommendations for use of DMARDs and biologic therapy in the perioperative period, The American…
Abstract Number: 2502 • 2018 ACR/ARHP Annual Meeting
Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis
Maria Martin-Lopez¹, Eliseo Albert², Esther Rodriguez-Almaraz³, Isidoro Gonzalez-Alvaro⁴, Mario Fernandez-Ruiz⁵, Jose M. Aguado⁵, David Navarro² and Jose L. Pablos⁶, ¹Rheumatology Department, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, ²Microbiology, Instituto de Investigación INCLIVA, Hospital Clínico, Valencia, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Instituto de Investigación Hospital 12 de Octubre. Unit of Infectious Diseases, Madrid, Spain, ⁶Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain, Madrid, Spain
Background/Purpose: Torque teno virus (TTV) is an endogenous anellovirus that is highly prevalent in adult healthy subjects (up to 90%) without known pathogenicity. Increased replication…
Abstract Number: 48 • 2018 ACR/ARHP Annual Meeting
In Vivo Demonstration of Tmtnf Reverse Signaling: Significance in the Therapeutic Response to Anti-TNF Agents during Murine Arthritis
Numa Simons¹, Andrey Kruglov², Yannick Degboe³, Arnaud Constantin³, Sergei Nedospasov⁴, Alain Cantagrel⁵, Jean-Luc Davignon⁶ and Benjamin Rauwel⁶, ¹Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, ²German Rheumatism Research Centre, Berlin, Germany, ³Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, ⁴4Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation, ⁵Center of Rheumatology of CHU, Toulouse, France, ⁶CPTP, INSERM UMR 1043, Toulouse, France
In vivo demonstration of tmTNF reverse signaling: significance in the therapeutic response to anti-TNF agents during murine arthritis. N. Simons1,2, A. Kruglov 3, Y. Degboé 1,2, A.…
Abstract Number: 1522 • 2018 ACR/ARHP Annual Meeting
Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
Xerxes Pundole¹, Natalia Zamora², Harish Siddhanamatha³, Jean Tayar⁴, Cheuk Hong Leung⁵, Heather Lin⁶ and Maria Suarez-Almazor⁷, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ³The University of Texas Health Science Center, School of Biomedical Informatics, Houston, TX, USA, Houston, TX, ⁴Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ⁵Department of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁶Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁷Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of rheumatoid arthritis (RA). But the use of bDMARDs in patients with RA…
Abstract Number: 2520 • 2018 ACR/ARHP Annual Meeting
Efficacy of the Reference Biologic Agents in Two Different Types of Randomized Clinical Trials: 1/ the Ones Comparing Their Efficacy Vs. Placebo and 2/ the Ones Comparing Their Efficacy Vs. Biosimilar in Rheumatoid Arthritis: A Systematic Review of Literature and Meta-Analysis
Lea Lopez¹, Christophe Richez², Marie-Elise Truchetet², Bernard Bannwarth³, Thomas Barnetche⁴ and Thierry Schaeverbeke⁵, ¹Aquitaine, Bordeaux, Bordeaux, France, ²Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU de Bordeaux, Bordeaux, France, ⁴Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, ⁵Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France
Background/Purpose: Recent randomized clinical trials (RCTs) have shown similar efficacy of biosimilar agents compared to reference agents. Is the efficacy of reference biologic agents different…
Abstract Number: 367 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease (IBD) Among Patients (Pts) with Other Chronic Inflammatory Diseases (CID) Treated with Interleukin-17a (IL-17a) or Phosphodiesterase 4 (PDE4) Inhibitors
Bruno Emond¹, Lorie A. Ellis², Soumya D Chakravarty³, Martin Ladouceur¹ and Patrick Lefebvre¹, ¹Analysis Group, Inc., Montréal, QC, Canada, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Scientific Affairs, LLC/Drexel University School of Medicine, Horsham/Phila, PA
Background/Purpose: IBD is often associated with other CID, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (PsO). Newer biologic agents…
Abstract Number: 1549 • 2018 ACR/ARHP Annual Meeting
Comparison of Adverse Events and Survival of Treatment in Patients with Rheumatoid Arthritis Receiving Combined Treatment of Methotrexate and Leflunomide Versus Those Receiving Biological Therapy
Magdalena Cavalieri¹, Roger Rolon Campuzano¹, Emilce E Schneeberger², Fernando Dal Pra³, Dafne Capelusnik⁴, Carolina Ayelen Isnardi⁵, Marina Natalia Fornaro⁶ and Gustavo Citera⁷, ¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Reumatology, Instituto de Rehabilitación Psicofísica, Argentina, CABA, Argentina, ⁵Reumatology, Instituto de Rehabilitación Psicofísica, CABA, Argentina, ⁶Section of Rheumatology, Instituto de Rehabilitación Psicofísica, buenos aires, Argentina, ⁷Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina
Background/Purpose: According to clinical practice guidelines for patients with rheumatoid arthritis (RA), after failure to a c-DMARD (conventional disease modifying antirheumatic drug) can be chosen…
Abstract Number: 2530 • 2018 ACR/ARHP Annual Meeting
Uncovering Clinicians’ Gaps and Attitudes Toward Biosimilars: Impact of a 2-Phase Educational Program
Zachary Schwartz¹, Jenny Schulz¹, Angelique Vinther¹, Alyce Kuklinski¹ and Kenneth Saag², ¹Clinical Care Options, Reston, VA, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biosimilar agents have changed the clinical landscape in rheumatology, gastroenterology, and dermatology. We sought to measure clinicians’ competence and knowledge of biosimilars and to…
Abstract Number: 550 • 2018 ACR/ARHP Annual Meeting
Biologic Discontinuation in Rheumatoid Arthritis: A Population Based Study 1999-2017
Michael Richter¹, Eric L. Matteson², John M. Davis III², Sara J. Achenbach³ and Cynthia S. Crowson³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN
Biologic discontinuation in rheumatoid arthritis: a population based study 1999-2017.Michael D Richter, Eric L Matteson, John M Davis III, Sara J Achenbach, Cynthia S Crowson…
Abstract Number: 1552 • 2018 ACR/ARHP Annual Meeting
No Effect of Concomitant Glucocorticoid Therapy on Efficacy and Safety of Tocilizumab Monotherapy Found in Rheumatoid Arthritis Clinical Trials
Mary Safy¹, Johannes W. G. Jacobs¹, Michael Edwardes², Maria JH de Hair¹, Xavier M Teitsma¹, Paco MJ Welsing¹, Michelle EA Borm³, Yves Luder⁴, Jacob van Laar¹, Attila Pethö-Schramm⁴ and Johannes W. J. Bijlsma⁵, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Everest Clinical Research, Markham, ON, Canada, ³Roche Nederland BV, Woerden, Netherlands, ⁴F. Hoffmann-La Roche, Basel, Switzerland, ⁵Rheumatology & Clinical Immunology department University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
No effect of concomitant glucocorticoid therapy on efficacy and safety of tocilizumab monotherapy in rheumatoid arthritis clinical trialsM. Safy1, J.W.G. Jacobs1, M. Edwardes2, M.J.H. de…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].